Search Results 401-410 of 16412 for infliximab
The performance characteristics of the ddPCR assay for the detection of ctDNA mutation in uveal melanoma patients will be assessed by comparing the mutation ...
Nilotinib belongs to the general group of medicines known as antineoplastics or cancer medicines. It interferes with the growth of cancer cells, which are ...
The purpose of this registry is to collect clinical, diagnostic, and therapeutic data specific for primary spinal column tumor patients, and evaluate it to ...
Infliximab; Ixekizumab; Lebrikizumab-lbkz; Leniolisib; Lovotibeglogene Autotemcel; Mirikizumab-mrkz; Mycophenolate Mofetil; Mycophenolic Acid; Nemolizumab-ilto ...
The trial will be conducted in 2 parts: an initial Dose Escalation Phase (Part A) of CA-4948 in patients with Relapsed or Refractory Non-Hodgkin Lymphoma, (RR ...
The purpose of this study is to compare IgG4-related disease remission and relapse rates between patients who had induction rituximab treatment with or without ...
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
FASN inhibitor TVB-2640 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as ...
Identifying biomarkers associated with failure vs success of immunosuppressive treatments (DMARD) tapering is a critical need which will allow to maximize the ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!